Abstract: A homogeneous interleukin 1.beta. (IL-1.beta.), its derivative having a modified amino acid sequence of IL-1.beta., a gene coding for said derivative, medical composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.beta. and the derivative.

Abstract: This invention provides an anti-tumor agent and a method for treating a tumor wherein gamma-interferon and interleukin-1 are used as active ingredients.

Abstract: A homogeneous interleukin 1.beta. (IL-1.beta.), its derivative having a modified amino acid sequence of IL-1.beta., a gene coding for said derivative, medical composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.beta. and the derivative.

Abstract: This invention provides medical uses of a M-CSF, particularly a method and composition for treating inflammatory disease and allergy using natural M-CSF or recombinant M-CSF or the derivatives thereof.

Abstract: The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a Il-1.alpha. derivative having an amino acid sequence of the formula (.alpha.) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.

Abstract: Methods are disclosed for promoting production of colony stimulating factor and inhibiting growth of Meth A tumor cells comprising administering a pharmaceutically effective amount of modified IL-1.alpha. to a subject.

Abstract: This invention relates to a biologically active recombinant human M-CSF obtained by expressing a human M-CSF gene coding for the amino acid sequence of the formula (1) in its entirety or devoid of a portion thereof; a process for preparing the recombinant human M-CSF; an expression plasmid containing the human M-CSF gene defined above; and a transformant haboring the above expression plasmid.

Abstract: Methods for stimulating immunity, inhibiting tumor growth, promoting production of a cytokine, and preventing or inhibiting radiation injury by administration of Interleukin-1.alpha. (IL-1.alpha.) derivatives, are disclosed.

Abstract: An interleukin-1.alpha. (IL-1.alpha.) derivative having a modified amino acid sequence of IL-1.alpha., a gene coding for said derivative, medicinal composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.alpha..

Abstract: The present invention provides a monoclonal antibody characterized in that the antibody has specific reactivity on human IL-1.beta., and a process for producing the antibody. The invention also provides a method for detection of biologically active human IL-1.beta..

Abstract: Interleukin-1.alpha. (IL-1-.alpha.) and derivatives, and their pharmaceutical compositions for use in treating arthritis or inflammation.

Abstract: Interleukin-1.beta. (IL-1.beta.) and derivatives, and their pharmaceutical compositions for use in treating arthritis or inflammation.

Abstract: A method for testing the inducibility of the hypothalamus to effect the secretion of andrenocorticotropic hormone comprising the steps of:(a) administering to a test subject a pharmaceutically effective amount of a derivative of human IL-1.beta. selected from the group consisting of human IL-1.beta. [7-153], human IL-1.beta. [1-148], human IL-1.beta. [Gly.sup.4 ], human IL-1.beta. [Leu.sup.93 ] and human IL-1.beta. [des Arg.sup.98]; and(b) measuring an increase in blood levels of at least one of adrenocorticotropic hormone, cortisol and corticotropin-releasing hormone,wherein the degree of increase in said blood levels of at least one of adrenocorticotropic hormone, cortisol and corticotropin-releasing hormone, corresponds to the degree of inducibility of the hypothalamus and is not substantially due to the induction of fever.

Abstract: The present invention provides a medicament for treating thrombocytopenia comprising as an active component at least one polypeptide selected from IL-1 and derivative thereof and a IL-1.alpha. derivative having an amino acid sequence of the formula (.alpha.) which is so modified as to fulfill at least one of the requirements of: deletion of the 16-position Arg; replacement of the 16-position Arg by another amino acid residue; deletion of the sequence of the 1-position Ser to the 14-position Phe and deletion of the amino acid sequence of the 1-position Ser to the 15-position Met.

Abstract: An interleukin-1.alpha. (IL-1.alpha.) derivative having a modified amino acid sequence of IL-1.alpha., a gene coding for said derivative, medicinal composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1.alpha..

Abstract: This invention provides an antitumor active substance GIF, a process for preparing the same, an antitumor composition containing the substance, a gene coding for GIF, a vector containing the gene and a recombinant microorganism, the substance GIF comprises as its component protein polypeptide A of the following primary structure. ##STR1## wherein X is Cys or Ser and Z is H or a peptide represented by the amino acid sequence ##STR2## or a peptide having the above sequence wherein at least one amino acid is removed from the N terminal or an amino acid.

Abstract: This invention provides a novel cultured cell line which is derived from human T leukemic cells and which produces a colony-stimulating factor (CSF). This invention also provides a process for preparing such human cultured cell line, and a process of producing a CSF from such cell line.